The Danish company that manufactures “Wegovy” and “Ozempic” complained that the US company, which produces competing weight-loss drugs “Zepbound” and “Mounjaro”, “deliberately chose outdated studies” in which “Eli Lilly’s” highest doses were compared to lower doses of “Novo Nordisk” drugs.
Read more «The New York Times»: The Trump administration demanded journalists’ phone data
The US company’s advertisement “falsely presented those results as proof that the product is clearly superior, while concealing or omitting essential clinical context,” the Danish company stated.
Read more Analysts revealed how many billions Hungary’s OTP Bank will pay for Luminor
